| Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies D Makower, A Rozenblit, H Kaufman, M Edelman, ME Lane, J Zwiebel, ... Clinical cancer research 9 (2), 693-702, 2003 | 215 | 2003 |
| A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells ME Lane, B Yu, A Rice, KE Lipson, C Liang, L Sun, C Tang, G McMahon, ... Cancer research 61 (16), 6170-6177, 2001 | 201 | 2001 |
| Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in … N Chan, A Willis, N Kornhauser, MM Ward, SB Lee, E Nackos, BR Seo, ... Clinical Cancer Research 23 (3), 666-676, 2017 | 175 | 2017 |
| Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I/II resectable non–small-cell lung cancer N Altorki, ME Lane, T Bauer, PC Lee, MJ Guarino, H Pass, E Felip, ... Journal of Clinical Oncology 28 (19), 3131-3137, 2010 | 170 | 2010 |
| 3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways P DelNero, M Lane, SS Verbridge, B Kwee, P Kermani, B Hempstead, ... Biomaterials 55, 110-118, 2015 | 136 | 2015 |
| Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse S Jain, J Cohen, MM Ward, N Kornhauser, E Chuang, T Cigler, A Moore, ... Annals of oncology, mds654, 2013 | 91 | 2013 |
| Lung biopsy: special techniques MD Cham, ME Lane, CI Henschke, DF Yankelevitz Seminars in respiratory and critical care medicine 29 (04), 335-349, 2008 | 69 | 2008 |
| Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity SE Stanton, MM Ward, P Christos, R Sanford, C Lam, MV Cobham, ... BMC cancer 15 (1), 267, 2015 | 67 | 2015 |
| Downregulation of cyclin D1 alters cdk 4-and cdk 2-specific phosphorylation of retinoblastoma protein B Yu, ME Lane, RG Pestell, C Albanese, S Wadler Molecular Cell Biology Research Communications 3 (6), 352-359, 2000 | 52 | 2000 |
| Microporosity of the substratum regulates differentiation of MDCK cells in vitro JR Cook, BE Crute, LM Patrone, J Gabriels, ME Lane, RG van Buskirk In Vitro Cellular & Developmental Biology-Plant 25 (10), 914-922, 1989 | 52 | 1989 |
| Incremental increase in VEGFR1+ hematopoietic progenitor cells and VEGFR2+ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients S Jain, MM Ward, J O’Loughlin, M Boeck, N Wiener, E Chuang, T Cigler, ... Breast cancer research and treatment 132 (1), 235-242, 2012 | 41 | 2012 |
| Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants S Wadler, B Yu, JY Tan, R Kaleya, A Rozenblit, D Makower, M Edelman, ... Clinical cancer research 9 (1), 33-43, 2003 | 41 | 2003 |
| SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells B Yu, ME Lane, S Wadler Biochemical pharmacology 64 (7), 1091-1100, 2002 | 33 | 2002 |
| Ixabepilone‐induced mitochondria and sensory axon loss in breast cancer patients GJ Ebenezer, K Carlson, D Donovan, M Cobham, E Chuang, A Moore, ... Annals of Clinical and Translational Neurology 1 (9), 639-649, 2014 | 32 | 2014 |
| Overcoming the response plateau in multiple myeloma: A novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization R Niesvizky, TM Mark, M Ward, DS Jayabalan, RN Pearse, M Manco, ... Clinical Cancer Research 19 (6), 1534-1546, 2013 | 29 | 2013 |
| Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer AJ Ocean, P Christos, JA Sparano, D Matulich, A Kaubish, A Siegel, ... Cancer chemotherapy and pharmacology 68 (2), 379-388, 2011 | 29 | 2011 |
| Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach AJ Ocean, P Christos, JA Sparano, MA Shah, RK Yantiss, J Cheng, J Lin, ... Investigational new drugs 32 (3), 542-548, 2014 | 17 | 2014 |
| Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 S Loi, P Schmid, J Cortés, DW Cescon, EP Winer, D Toppmeyer, ... Cancer Research 79 (13 Supplement), LB-225-LB-225, 2019 | 16 | 2019 |
| A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with breast cancer (BC) at high risk for recurrence: Updated results. S Sahota, N Kornhauser, A Willis, MM Ward, T Cigler, A Moore, ... Journal of Clinical Oncology 35 (15_suppl), 2557-2557, 2017 | 9 | 2017 |
| In vivo synergy between oncolytic reovirus and gemcitibane in ras-mutated human HCT116 xenografts M Lane, J Fahey, C Besanceney, N Hamel, B Yu, B Thompson, M Coffey, ... Cancer Research 67 (9 Supplement), 4812-4812, 2007 | 9 | 2007 |
